SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018.
Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.
Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.
The full speaker line-up and conference agenda is available at http://www.adcsummit.com/benth